May 23, 2011
After an accelerated review, the European Medicines Agency's Committee for Medicinal Products for Human Use has endorsed Victrelis (boceprevir), Merck's new hepatitis C treatment, and recommended that the European Commission grant marketing approval. The committee said Victrelis should be used in combination with interferon-based treatment in untreated patients with chronic hepatitis C, as well as in patients who had failed on treatment. The action came just a week after the drug was approved by the US Food and Drug Administration.
No comments have been made.
|Using Saliva as Lube Can Cause Rectal Gonorrhea|
|This Week in HIV Research: Enzyme May Reduce Cardiovascular Disease Risk, and New Insights Into an HIV Vaccine|
|This Week in HIV Research: Determinants of Cognitive Impairment, and Discovery of 'Teenage' Broadly Neutralizing Antibody|
|FDA Approves Descovy, an Updated Version of Truvada -- But Not for PrEP|
|What Should the Next U.S. President Do to Advance the Fight Against HIV?|